{
  "page_1": [
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        170.43,
        62.89,
        424.45,
        83.87
      ],
      "y0": 62.89,
      "content": "조사우수사례 평가 보고서"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        429.37,
        98.89,
        553.1,
        110.88
      ],
      "y0": 98.89,
      "content": "(’25上 평가번호 : 14 )"
    },
    {
      "type": "yellow_table",
      "color": "yellow",
      "bbox": [
        42.0,
        125.5,
        553.5,
        181.5
      ],
      "y0": 125.5,
      "content": "개인·법인\n업종(코드)\n조사유형\n외형구간\n조사청\n법인\n제조(242301)\n비정기\n351억원대\n지방청"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        47.97,
        207.4,
        211.92,
        226.35
      ],
      "y0": 207.4,
      "content": "Ⅰ\n조사성과(결과)"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        49.65,
        252.92,
        174.39,
        270.89
      ],
      "y0": 252.92,
      "content": "가. 조사대상개요"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        49.89,
        287.09,
        552.42,
        303.92
      ],
      "y0": 287.09,
      "content": "○조사법인은‘0X년5월설립하여경피약품전달시스템기술기반으로패치형"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        70.88,
        310.22,
        552.42,
        327.04
      ],
      "y0": 310.22,
      "content": "의약품및치매치료제(도네패질) 패치개량신약개발을주업으로하여’1X.7월"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        70.88,
        332.64,
        170.43,
        349.45
      ],
      "y0": 332.64,
      "content": "코스닥특례상장"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        59.97,
        359.97,
        552.42,
        376.78
      ],
      "y0": 359.97,
      "content": "- ‘2X년10월도네패질패치제품의중남미00개국에서의판매라이센스및"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        382.38,
        442.32,
        399.21
      ],
      "y0": 382.38,
      "content": "제품공급에관한계약을㈜☆☆☆☆과체결해주가상승"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        49.65,
        419.66,
        136.61,
        437.63
      ],
      "y0": 419.66,
      "content": "나. 적출성과"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        56.49,
        452.98,
        175.46,
        469.81
      ],
      "y0": 452.98,
      "content": "○주요적출내역"
    },
    {
      "type": "yellow_table",
      "color": "yellow",
      "bbox": [
        70.5,
        478.5,
        552.0,
        654.0
      ],
      "y0": 478.5,
      "content": "연번\n조사항목\n코드\n적출요지(결정경정사유)\n①\n가공매입매입세액\n(리베이트지급관련)\n20402\n리베이트재원마련을위해가공경비계상(가\n공세금계산서수취)\n②\n부당행위계산의부인\n(자산저가양도)\n11302\n사주에게전환사채콜옵션저가양도부당\n행위\n③\n④\n⑤"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        49.41,
        667.55,
        552.42,
        684.38
      ],
      "y0": 667.55,
      "content": "○(최초적출사례) 제약회사의의약품처방실적에대한대가(리베이트) 지급"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        70.4,
        689.25,
        175.35,
        706.06
      ],
      "y0": 689.25,
      "content": "적출하여과세함"
    }
  ],
  "page_2": [
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        47.97,
        59.49,
        181.82,
        78.43
      ],
      "y0": 59.49,
      "content": "Ⅱ\n조사노하우"
    },
    {
      "type": "yellow_table",
      "color": "yellow",
      "bbox": [
        45.5,
        99.5,
        551.5,
        155.5
      ],
      "y0": 99.5,
      "content": "적출□\n1\nv 가공매입에 대한 매입세액 (항목코드: 20402)\n리베이트 재원 마련을 위해 가공경비(가공세금계산서) 계상"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        42.46,
        187.08,
        127.01,
        203.03
      ],
      "y0": 187.08,
      "content": "1. 조사착안"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        42.46,
        225.47,
        217.68,
        243.44
      ],
      "y0": 225.47,
      "content": "가. 착안사항도출과정"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        49.89,
        260.36,
        552.42,
        277.19
      ],
      "y0": 260.36,
      "content": "○조사법인은의약품영업과관련하여직접병원영업을하지않고하위"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        70.88,
        283.49,
        552.42,
        300.31
      ],
      "y0": 283.49,
      "content": "CSO와마케팅위탁계약을한후하위CSO가병의원영업을하여제출한"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        70.88,
        305.91,
        399.74,
        322.72
      ],
      "y0": 305.91,
      "content": "처방근거자료로수수료를지급하는것으로확인됨"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        59.97,
        333.24,
        552.42,
        350.05
      ],
      "y0": 333.24,
      "content": "- 조사법인의자료만으로의료인에게지급한리베이트를찾는게불가능하고"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        355.65,
        552.42,
        372.47
      ],
      "y0": 355.65,
      "content": "병의원직접영업을하는하위CSO를조사해야리베이트유무를확인할수"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        378.07,
        435.0,
        394.88
      ],
      "y0": 378.07,
      "content": "있다고판단하여관련하위CSO를추가선정하여조사함"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        42.46,
        422.39,
        127.01,
        438.33
      ],
      "y0": 422.39,
      "content": "2. 조사기법"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        42.46,
        460.78,
        217.08,
        478.74
      ],
      "y0": 460.78,
      "content": "가. 적출항목조사방법"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        49.41,
        494.94,
        552.4,
        511.77
      ],
      "y0": 494.94,
      "content": "○(1차CSO 선정) 조사법인과의약품영업으로마케팅위탁계약을한CSO"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        70.4,
        517.23,
        552.42,
        534.05
      ],
      "y0": 517.23,
      "content": "업체는10여곳으로확인되어CSO와의거래내역을상세히분석한후세금"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        70.4,
        539.65,
        504.21,
        556.47
      ],
      "y0": 539.65,
      "content": "탈루혐의가있는업체를조사대상자로추가선정하여조사진행함"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        59.97,
        566.98,
        552.42,
        583.8
      ],
      "y0": 566.98,
      "content": "- 조사결과병의원의의사들에게지급한사실확인되지않고동업체도제약"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        589.4,
        552.42,
        606.21
      ],
      "y0": 589.4,
      "content": "회사로부터수수료를받은후다시하위CSO에게수수료를지급하고있는"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        611.81,
        162.51,
        628.63
      ],
      "y0": 611.81,
      "content": "사실을확인함"
    },
    {
      "type": "blue_table",
      "color": "blue",
      "bbox": [
        69.0,
        647.0,
        552.0,
        756.0
      ],
      "y0": 647.0,
      "path": "crops/page_002\\blue_000.png"
    }
  ],
  "page_3": [
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        49.41,
        62.81,
        552.42,
        79.64
      ],
      "y0": 62.81,
      "content": "○(2차CSO 선정) 1차CSO 조사로도리베이트적출이불가능함을확인하고"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        70.4,
        85.11,
        552.42,
        101.92
      ],
      "y0": 85.11,
      "content": "동업체의28개의매입처를일일이정밀검토하여최하위CSO로추정되는"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        70.4,
        107.52,
        367.12,
        124.34
      ],
      "y0": 107.52,
      "content": "업체를조사대상자로추가선정하여조사진행"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        59.97,
        134.85,
        552.42,
        151.67
      ],
      "y0": 134.85,
      "content": "- 최하위CSO 선정시제약회사근무이력이있고, 하위CSO 위탁없이병의원에"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        157.27,
        552.42,
        174.08
      ],
      "y0": 157.27,
      "content": "직접영업하는것으로추정되며, 소득세및부가세탈루혐의가있는업체를"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        179.68,
        486.62,
        196.5
      ],
      "y0": 179.68,
      "content": "선정하였음(리베이트제공으로적정경비반영이어려울것으로판단)"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        49.65,
        216.84,
        212.17,
        234.81
      ],
      "y0": 216.84,
      "content": "나. 핵심증거자료확보"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        49.41,
        251.01,
        552.42,
        267.84
      ],
      "y0": 251.01,
      "content": "○(계좌이체내역확인) 조사시계좌내역을검토한바본인및모친의사업자"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        273.3,
        552.42,
        290.12
      ],
      "y0": 273.3,
      "content": "계좌로수수료수령후다시본인의타계좌로자금을이체한후병의원"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        295.72,
        421.33,
        312.53
      ],
      "y0": 295.72,
      "content": "원장에게수시로자금이계좌이체되고있음을확인함"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        49.41,
        328.08,
        552.42,
        344.91
      ],
      "y0": 328.08,
      "content": "○(리베이트확정) 기조사한1차CSO의‘조사법인의약품판매정산내역’을"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        350.5,
        552.42,
        367.31
      ],
      "y0": 350.5,
      "content": "확보하여확인한바, 동업체가상위CSO(1차CSO)에의약품판매정산내역을"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        372.79,
        552.42,
        389.61
      ],
      "y0": 372.79,
      "content": "송부하면수수료를수취하고받은수수료의일부(70%정도*)를10여분이내"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        395.21,
        509.84,
        412.02
      ],
      "y0": 395.21,
      "content": "로병의원원장에게이체하고있어처방실적에대한대가로확정함"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        68.36,
        417.74,
        552.3,
        433.28
      ],
      "y0": 417.74,
      "content": "* 복제의약품의경우보험약가의40%～50%가CSO 수수료로지급되므로결국"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        76.4,
        438.6,
        334.5,
        454.14
      ],
      "y0": 438.6,
      "content": "보험약가의30% 정도가리베이트로지급됨"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        49.41,
        469.17,
        552.42,
        486.0
      ],
      "y0": 469.17,
      "content": "○(가공경비적출) 리베이트제공분에대한경비처리가어려워서허위경비를"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        491.46,
        552.42,
        508.28
      ],
      "y0": 491.46,
      "content": "계상하기위해가공매입세금계산서를수취한사실을적출하여매입세액"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        513.88,
        127.49,
        530.69
      ],
      "y0": 513.88,
      "content": "불공제함"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        49.65,
        551.16,
        143.8,
        569.12
      ],
      "y0": 551.16,
      "content": "다. 처분유지"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        49.41,
        585.2,
        552.42,
        602.03
      ],
      "y0": 585.2,
      "content": "○(기타소득인정) 의약품처방실적과이에대한수수료의일부를계좌이체한"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        70.4,
        607.62,
        552.42,
        624.43
      ],
      "y0": 607.62,
      "content": "내역을대사하여리베이트를받은혐의로병의원원장에게거래사실확인서를"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        70.4,
        629.91,
        548.82,
        646.73
      ],
      "y0": 629.91,
      "content": "발송하였고, 간접적으로세무대리인을통해서리베이트를받은사실을인정함"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        59.97,
        657.36,
        552.42,
        674.18
      ],
      "y0": 657.36,
      "content": "- 리베이트를제공받은병원장은필요경비없는기타소득에해당함을인정"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        679.66,
        455.87,
        696.47
      ],
      "y0": 679.66,
      "content": "하고이를반영하여종합소득세수정신고하였음을확인함"
    }
  ],
  "page_4": [
    {
      "type": "yellow_table",
      "color": "yellow",
      "bbox": [
        45.5,
        62.5,
        551.5,
        118.0
      ],
      "y0": 62.5,
      "content": "적출□\n2\nv 부당행위 계산의 부인 (항목코드: 11302)\n사주에 전환사채 콜옵션 저가 양도분 부당행위계산 부인"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        42.46,
        145.04,
        132.41,
        162.07
      ],
      "y0": 145.04,
      "content": "1. 조사착안"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        42.46,
        185.2,
        217.68,
        203.16
      ],
      "y0": 185.2,
      "content": "가. 착안사항도출과정"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        49.41,
        219.24,
        457.67,
        236.07
      ],
      "y0": 219.24,
      "content": "○전환사채콜옵션은성격상별도의파생상품자산에해당함"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        59.97,
        246.69,
        551.7,
        263.51
      ],
      "y0": 246.69,
      "content": "- ’22.5월금융위원회에서는‘제3자지정콜옵션부전환사채’ 관련콜옵션을"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        268.99,
        552.42,
        285.82
      ],
      "y0": 268.99,
      "content": "전환사채와는구분·분리된‘별도의파생상품자산’으로정의하며「전환"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        291.4,
        400.34,
        308.23
      ],
      "y0": 291.4,
      "content": "사채콜옵션회계처리」에대한감독지침을안내함"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        49.41,
        323.77,
        392.31,
        340.6
      ],
      "y0": 323.77,
      "content": "○금융감독원조사결과사주의고발조치내역확인"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        59.97,
        351.1,
        552.42,
        367.91
      ],
      "y0": 351.1,
      "content": "- 조사법인사주는자산운용사대표와공모하여CB 콜옵션을이용이익을"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        372.43,
        552.42,
        390.33
      ],
      "y0": 372.43,
      "content": "얻기위해수익차등형펀드*를만들고사주자녀법인이2종수익자로서"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        395.93,
        162.39,
        412.74
      ],
      "y0": 395.93,
      "content": "11억원투자함"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        79.64,
        439.2,
        272.73,
        454.74
      ],
      "y0": 439.2,
      "content": "80% 이상분배받는구조의펀드"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        59.97,
        464.85,
        552.42,
        481.67
      ],
      "y0": 464.85,
      "content": "- 사주는조사법인으로부터CB 콜옵션을1.2억원(CB 액면가의1%)에양수한후"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        487.15,
        552.42,
        503.96
      ],
      "y0": 487.15,
      "content": "즉시펀드에양도하였으며, 해당펀드는CB 콜옵션행사및전환권행사하여"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        509.56,
        543.19,
        526.38
      ],
      "y0": 509.56,
      "content": "이익을얻은부분에부정거래행위금지등위반등에대해“고발” 조치함"
    },
    {
      "type": "blue_table",
      "color": "blue",
      "bbox": [
        84.5,
        541.5,
        550.5,
        770.0
      ],
      "y0": 541.5,
      "path": "crops/page_004\\blue_000.png"
    }
  ],
  "page_5": [
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        42.46,
        67.61,
        256.66,
        85.57
      ],
      "y0": 67.61,
      "content": "나. 착안사항관련내용검토"
    },
    {
      "type": "blue_table",
      "color": "blue",
      "bbox": [
        87.5,
        100.0,
        552.0,
        208.5
      ],
      "y0": 100.0,
      "path": "crops/page_005\\blue_000.png"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        42.46,
        238.06,
        132.41,
        255.09
      ],
      "y0": 238.06,
      "content": "2. 조사기법"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        42.46,
        278.1,
        213.84,
        296.06
      ],
      "y0": 278.1,
      "content": "가. 적출항목조사방법"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        49.41,
        312.26,
        161.43,
        329.09
      ],
      "y0": 312.26,
      "content": "○사실관계확인"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        59.97,
        339.59,
        551.7,
        356.4
      ],
      "y0": 339.59,
      "content": "- (CB 콜옵션부여) 조사법인은’19년제2회차전환사채350억원, 3회차전환"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        362.0,
        552.42,
        378.82
      ],
      "y0": 362.0,
      "content": "사채50억원을발행하면서권면총액의최대30%에해당하는콜옵션을부여"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        384.3,
        400.34,
        401.12
      ],
      "y0": 384.3,
      "content": "하면서발행법인이콜옵션행사자를지정하도록함"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        59.97,
        411.75,
        552.42,
        428.57
      ],
      "y0": 411.75,
      "content": "- (콜옵션지정) 조사법인은이사회결의를통해콜옵션행사자를사주(대표"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        434.05,
        552.42,
        450.86
      ],
      "y0": 434.05,
      "content": "이사)에게지정하고콜옵션에대한객관적인평가없이사주로부터콜옵션"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        456.46,
        397.95,
        473.28
      ],
      "y0": 456.46,
      "content": "행사대상전환사채120억원의1%를대가로수취함"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        59.97,
        483.79,
        551.7,
        500.62
      ],
      "y0": 483.79,
      "content": "- (콜옵션양도) 사주는부여받은콜옵션을‘’○○전문투자신탁펀드”에양도"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        506.21,
        552.42,
        523.02
      ],
      "y0": 506.21,
      "content": "하고펀드로하여금콜옵션을행사하게하여전환권행사및주식을매도"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        528.62,
        463.31,
        545.44
      ],
      "y0": 528.62,
      "content": "하여2종수익자로투자한자녀법인이투자수익을얻도록함"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        49.41,
        560.99,
        552.42,
        577.82
      ],
      "y0": 560.99,
      "content": "○(콜옵션시가산정) 조사법인이발행한제2·3차전환사채콜옵션권리평가는"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        70.4,
        583.28,
        552.42,
        600.11
      ],
      "y0": 583.28,
      "content": "사주를콜옵션행사자로지정한아이큐어㈜이사회결의일(부당행위계산부인"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        70.4,
        605.7,
        552.42,
        622.51
      ],
      "y0": 605.7,
      "content": "규정적용시점)을평가기준일로하여외부전문평가기관평가금액을거래"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        70.4,
        628.11,
        161.43,
        644.93
      ],
      "y0": 628.11,
      "content": "시가로결정함"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        49.29,
        670.43,
        236.51,
        687.24
      ],
      "y0": 670.43,
      "content": "나. 납세자주장및과세논리"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        49.41,
        702.79,
        552.42,
        719.62
      ],
      "y0": 702.79,
      "content": "○(납세자주장) 조사법인이얻어야할경제적이익을포기한것이없으므로"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        75.68,
        725.21,
        254.14,
        742.02
      ],
      "y0": 725.21,
      "content": "이익분여자로볼수없으며,"
    }
  ],
  "page_6": [
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        59.97,
        57.78,
        552.42,
        74.59
      ],
      "y0": 57.78,
      "content": "- 사주는쟁점거래를통해이익을얻을목적도없었고실제로이익을얻지도"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        80.19,
        552.42,
        97.01
      ],
      "y0": 80.19,
      "content": "못했음에도불구하고, 이익이분여된거래당사자로보아소득처분(상여)하는"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        102.49,
        319.87,
        119.3
      ],
      "y0": 102.49,
      "content": "것은실질과세원칙에부합하지않으며,"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        59.97,
        128.86,
        552.42,
        145.67
      ],
      "y0": 128.86,
      "content": "- 거래목적은투자신탁의투자유치인바, 경제적합리성이결여되었다고"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        151.27,
        148.48,
        168.09
      ],
      "y0": 151.27,
      "content": "보기어려움"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        49.41,
        183.64,
        552.42,
        200.47
      ],
      "y0": 183.64,
      "content": "○(조사팀과세논리) 조사법인이사주를CB 콜옵션행사자로지정시적정"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        70.4,
        206.05,
        551.7,
        222.87
      ],
      "y0": 206.05,
      "content": "대가를수취하여야함에도불구하고낮은대가를수취하였으므로부당행위"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        70.4,
        228.35,
        345.53,
        245.17
      ],
      "y0": 228.35,
      "content": "계산부인규정을적용하는것이타당하며,"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        59.97,
        255.8,
        552.42,
        272.62
      ],
      "y0": 255.8,
      "content": "- 사주는자산운용사대표와공모하여쟁점거래를계획하여실행하였으며,"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        278.1,
        552.42,
        294.91
      ],
      "y0": 278.1,
      "content": "쟁점콜옵션을저가로취득한것이명백하므로법인과특수관계자와의거래에"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        300.51,
        549.78,
        317.33
      ],
      "y0": 300.51,
      "content": "있어서부당행위계산부인대상이적용되는바, 법인세법의소득처분은정당함"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        59.97,
        327.84,
        552.42,
        344.66
      ],
      "y0": 327.84,
      "content": "- 쟁점거래는금융감독원조사결과에따르면사주가이익을얻기위해공모한"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        350.26,
        449.4,
        367.07
      ],
      "y0": 350.26,
      "content": "정황이확인되므로경제적합리성이없는거래임이명백함"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        49.65,
        387.54,
        174.39,
        405.5
      ],
      "y0": 387.54,
      "content": "다. 과세요건검토"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        49.41,
        421.58,
        552.42,
        438.41
      ],
      "y0": 421.58,
      "content": "○(자산의저가양도) 조사법인이발행한CB 콜옵션권리는독립적으로양도"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        70.88,
        443.99,
        552.41,
        460.82
      ],
      "y0": 443.99,
      "content": "가능한‘별도의파생상품자산’에해당하므로사주를콜옵션행사자로지정·"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        70.88,
        466.29,
        421.45,
        483.11
      ],
      "y0": 466.29,
      "content": "대가수취행위는‘자산의저가양도’ 손익거래에해당함"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        49.41,
        498.66,
        552.42,
        515.48
      ],
      "y0": 498.66,
      "content": "○(콜옵션적정가치불분명) 조사법인이사주를CB 콜옵션행사자로지정"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        72.32,
        521.07,
        411.62,
        537.89
      ],
      "y0": 521.07,
      "content": "하여받은대가에대한구체적인산정근거가없으며,"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        59.97,
        548.4,
        552.42,
        565.22
      ],
      "y0": 548.4,
      "content": "- 콜옵션의적정가치를평가하지아니하고임의금액으로양도한사실은경제적"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        570.82,
        552.42,
        587.63
      ],
      "y0": 570.82,
      "content": "합리성이결여된행위로서, 법인세법상부당행위계산부인규정을적용하는"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        593.23,
        148.48,
        610.05
      ],
      "y0": 593.23,
      "content": "것이타당함"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        49.41,
        625.6,
        552.42,
        642.43
      ],
      "y0": 625.6,
      "content": "○(부당행위계산부인적용시점) 조사법인이사주를콜옵션행사자로지정한"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        70.88,
        647.89,
        496.41,
        664.71
      ],
      "y0": 647.89,
      "content": "이사회결의일(‘20.12.17.)을부당행위발생시점으로봄이타당하며,"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        112.02,
        683.49,
        379.33,
        700.32
      ],
      "y0": 683.49,
      "content": "참고\n기획재정부법인세제과- 48, 2016.01.18"
    },
    {
      "type": "blue_table",
      "color": "blue",
      "bbox": [
        76.5,
        701.0,
        541.0,
        780.5
      ],
      "y0": 701.0,
      "path": "crops/page_006\\blue_000.png"
    }
  ],
  "page_7": [
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        59.97,
        57.78,
        552.42,
        74.61
      ],
      "y0": 57.78,
      "content": "- 이는법인세법제52조【부당행위계산의부인】및같은법시행령제88조"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        80.19,
        552.42,
        97.02
      ],
      "y0": 80.19,
      "content": "【부당행위계산의유형등】제1항제3호규정의‘자산을무상또는시가"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        71.48,
        102.49,
        446.28,
        119.3
      ],
      "y0": 102.49,
      "content": "보다낮은가액으로양도또는현물출자한경우’에해당함"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        49.65,
        139.77,
        257.14,
        157.73
      ],
      "y0": 139.77,
      "content": "라. 도전적과세및처분유지"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        49.41,
        173.81,
        552.42,
        190.64
      ],
      "y0": 173.81,
      "content": "○조사항목에대한세법해석자료, 심판례등합리적과세근거를제시하고,"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        66.92,
        196.23,
        552.42,
        213.04
      ],
      "y0": 196.23,
      "content": "사전심의를통해정당한과세논리를구축하였으며, 조사법인에충분한의견"
    },
    {
      "type": "purple_text",
      "color": "purple",
      "bbox": [
        66.92,
        218.64,
        358.13,
        235.46
      ],
      "y0": 218.64,
      "content": "제출기회를제공하여과세품질제고에힘씀"
    }
  ]
}